Related Experiment Video
Updated: Jan 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells
Zhilei Cui1, Zhen Liu2, Junxiang Zeng3
1Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.
Aims:
The relationship between TRIM59 and drug resistance is elusive despite of its multiple uncovered roles in human cancers. Here we aimed to characterize the expression status of TRIM59 in gefitinib-resistant EGFR mutant lung adenocarcinoma cells and elucidate its mechanism underlying the drug resistance.
Main Methods:
Gefitinib-resistant cell lines were established by progressive dosage. Relative expression of TRIM59 was determined by both real-time PCR and Western blot. Target gene knockdown was achieved by specific shRNAs. Cell viability was measured by MTT assay. Cell apoptosis was analyzed by flow cytometry with Annexin V/7-AAD double staining. Cell proliferation was determined by clonogenic formation assay. Migration and invasion capacities were detected using transwell chamber assay. Direct interaction between TRIM59 and STAT3 was analyzed by co-immunoprecipitation assay.
Key Findings:
We first observed overexpression of TRIM59 in gefitinib-resistant EGFR mutant lung adenocarcinoma cells. ShRNA-mediated knockdown of TRIM59 significantly inhibited cell viability and stimulated apoptosis. Meanwhile, TRIM59-deficiency suppressed cell migration and invasion. We further identified the interaction between TRIM59 and STAT3. TRIM59-deficiency remarkably impaired the activation of STAT3 signaling. STAT3-specific shRNAs significantly re-sensitized TRIM59-proficient EGFR mutant lung adenocarcinoma cells to gefitinib.
Significance:
Our data characterized aberrant TRIM59 overexpression in gefitinib-resistance EGFR mutant lung adenocarcinoma cells, and indicated the potential involvement of TRIM59-STAT3 signaling in the occurrence of gefitinib-resistance.
Insights
Overexpression of TRIM59 in lung cancer cells contributes to gefitinib resistance by activating STAT3 signaling. Targeting TRIM59 or STAT3 may overcome drug resistance in EGFR-mutant lung adenocarcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The role of TRIM59 in drug resistance remains unclear despite its known functions in human cancers.
- Gefitinib resistance is a significant challenge in treating EGFR-mutant lung adenocarcinoma.
Purpose of the Study:
- To investigate TRIM59 expression in gefitinib-resistant EGFR-mutant lung adenocarcinoma cells.
- To elucidate the mechanism by which TRIM59 contributes to gefitinib resistance.
Main Methods:
- Established gefitinib-resistant cell lines through progressive dosage.
- Quantified TRIM59 expression using real-time PCR and Western blot.
- Assessed cell viability, apoptosis, proliferation, migration, and invasion following TRIM59 knockdown via shRNA.
- Analyzed TRIM59-STAT3 interaction using co-immunoprecipitation.
Main Results:
- TRIM59 was overexpressed in gefitinib-resistant cells.
- TRIM59 knockdown reduced cell viability, induced apoptosis, and suppressed migration/invasion.
- TRIM59 interacts with STAT3, and its deficiency impairs STAT3 activation.
- STAT3 knockdown resensitized cells to gefitinib.
Conclusions:
- Aberrant TRIM59 overexpression is linked to gefitinib resistance in EGFR-mutant lung adenocarcinoma.
- The TRIM59-STAT3 signaling pathway is implicated in the development of gefitinib resistance.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Lung Capacity
Resistivity
Resistance
Anaphase Promoting Complex